Physostigmine should be used more readily for antimuscarinic toxicity: PRO
Proponents suggest physostigmine is the preferred treatment for antimuscarinic toxicity. Its use has a clear biological rationale and is supported by extensive clinical use which demonstrated effectiveness and safety.
Source:
British Journal of Clinical Pharmacology
SPS commentary:
In an opposing article, the author acknowledges physostigmine is the drug of choice for treating antimuscarinic (anticholinergic) toxicity—when treatment is necessary for the right patient- not for every patient with antimuscarinic symptoms. Patient selection is key.